泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03347 泰格医药

已收盘 07-15 16:08:28

47.650

-0.900

-1.85%

最高48.600	最低46.300	成交量476.48万
今开48.550	昨收48.550	日振幅4.74%
总市值410.27亿	流通市值58.61亿	总股本8.61亿
成交额2.25亿	换手率3.87%	流通股本1.23亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03347","market":"HK","secType":"STK","nameCN":"泰格医药","latestPrice":47.65,"timestamp":1752566908007,"preClose":48.55,"halted":0,"volume":4764800,"delay":0,"floatShares":123000000,"shares":861000000,"eps":0.5134363545804224,"marketStatus":"已收盘","change":-0.9,"latestTime":"07-15 16:08:28","open":48.55,"high":48.6,"low":46.3,"amount":224780110,"amplitude":0.047374,"askPrice":47.65,"askSize":10800,"bidPrice":47.6,"bidSize":900,"shortable":3,"etf":0,"ttmEps":0.4251976670068294,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1752629400000},"marketStatusCode":5,"adr":0,"listingDate":1596729600000,"exchange":"SEHK","adjPreClose":48.55,"dividendRate":0.006875,"openAndCloseTimeList":[[1752543000000,1752552000000],[1752555600000,1752566400000]],"volumeRatio":0.575374,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"300347","market":"SZ","secType":"STK","nameCN":"泰格医药","latestPrice":57.31,"timestamp":1752562800000,"preClose":58.15,"halted":0,"volume":13036800,"delay":0,"premium":"-23.98"}},"requestUrl":"/m/hq/s/03347","defaultTab":"news","newsList":[{"id":"2551157660","title":"海思科(002653.SZ)：创新药HSK47388片获得FDA同意开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2551157660","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551157660?lang=zh_cn&edition=full","pubTime":"2025-07-15 16:46","pubTimestamp":1752569200,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科(002653.SZ)披露近日收到美国食品药品监督管理局(“FDA”)的 Study May Proceed Letter，根据FDA相关规定，经审查，公司2025年5月递交的HSK47388片临床试验申请符合药品注册的有关要求，同意本品开展临床试验。公告称，HSK47388片是公司自主研发的口服、强效、高选择性的药物，拟用于自身免疫疾病的治疗。临床前研究结果显示，HSK47388可以剂量依赖地抑制大鼠炎症反应，同时也表现出了良好的耐受性和较大的安全窗，是一款极具开发潜力的药物，有望为自身免疫疾病患者提供一种新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1317973.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002653","BK0077","BK0188","BK1161","159992","03347","BK0028","BK1574","BK1141","BK0239","BK0033","BK1576","BK1583","06978"],"gpt_icon":0},{"id":"2551163310","title":"每日卖空追踪 | 泰格医药 07月15日卖空量成交14.26万股，卖空比例为2.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551163310","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551163310?lang=zh_cn&edition=full","pubTime":"2025-07-15 16:30","pubTimestamp":1752568231,"startTime":"0","endTime":"0","summary":"泰格医药北京时间07月15日，跌1.85%，卖空量成交14.26万股%，较上一交易日减少82.16%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715172622a6aace1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715172622a6aace1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1583","03347","BK1576"],"gpt_icon":0},{"id":"2551770901","title":"新诺威：SYS6040临床试验目前正常开展中","url":"https://stock-news.laohu8.com/highlight/detail?id=2551770901","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551770901?lang=zh_cn&edition=full","pubTime":"2025-07-14 17:33","pubTimestamp":1752485592,"startTime":"0","endTime":"0","summary":"证券之星消息，新诺威(300765)07月14日在投资者关系平台上答复投资者关心的问题。投资者提问：SYS6040实验进展如何新诺威回复：您好，感谢您对公司的关注，SYS6040临床试验目前正常开展中，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071400025395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226","BK1141","03347","BK1583","BK1576"],"gpt_icon":0},{"id":"2551900779","title":"每日卖空追踪 | 泰格医药 07月14日卖空量成交44.54万股，卖空比例为6.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551900779","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551900779?lang=zh_cn&edition=full","pubTime":"2025-07-14 16:30","pubTimestamp":1752481830,"startTime":"0","endTime":"0","summary":"泰格医药北京时间07月14日，跌3.09%，卖空量成交44.54万股%，较上一交易日减少2.3%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714172704a4499001&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714172704a4499001&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1583","03347","BK1576"],"gpt_icon":0},{"id":"2551973481","title":"泰格医药盘中异动 大幅跳水5.09%报47.550港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551973481","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551973481?lang=zh_cn&edition=full","pubTime":"2025-07-14 11:34","pubTimestamp":1752464056,"startTime":"0","endTime":"0","summary":"2025年07月14日临近午盘11时34分，泰格医药股票出现波动，股价快速下跌5.09%。截至发稿，该股报47.550港元/股，成交量388.804万股，换手率3.16%，振幅10.08%。资金方面，该股资金流入6401.78万港元，流出1.08824亿港元。泰格医药股票所在的生物技术行业中，整体跌幅为0.99%。其相关个股中，北海康成-B、博安生物、创胜集团-B涨幅较大，振幅较大的相关个股有北海康成-B、博安生物、创胜集团-B，振幅分别为25.68%、22.31%、15.85%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071411341697a5213b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071411341697a5213b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1576","BK1141","03347"],"gpt_icon":0},{"id":"2551919976","title":"每周股票复盘：复星医药（600196）复迈宁启动新临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2551919976","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551919976?lang=zh_cn&edition=full","pubTime":"2025-07-13 04:00","pubTimestamp":1752350434,"startTime":"0","endTime":"0","summary":"截至2025年7月11日收盘，复星医药报收于25.6元，较上周的25.43元上涨0.67%。本周，复星医药7月10日盘中最高价报26.05元。复星医药当前最新总市值683.63亿元，在化学制药板块市值排名6/150，在两市A股市值排名208/5149。本周关注点公司公告汇总：复星医药启动复迈宁治疗儿童低级别脑胶质瘤的Ⅲ期临床试验公司公告汇总复星医药关于控股子公司药品临床试验进展的公告指出，近日启动了复迈宁用于治疗儿童低级别脑胶质瘤在中国境内的Ⅲ期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071300000715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK1593","BK0196","02196","BK1515","BK0175","BK0060","BK1141","BK0239","BK1583","BK0012","BK0183","600196","BK0188","03347","BK1191","BK1576","BK0187","BK0096"],"gpt_icon":0},{"id":"2551199489","title":"每周股票复盘：吉贝尔（688566）抗肿瘤新药获准临床试验联合用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2551199489","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551199489?lang=zh_cn&edition=full","pubTime":"2025-07-13 03:58","pubTimestamp":1752350288,"startTime":"0","endTime":"0","summary":"截至2025年7月11日收盘，吉贝尔报收于29.4元，较上周的29.34元上涨0.2%。本周，吉贝尔7月11日盘中最高价报30.52元。本周关注点公司公告汇总: 吉贝尔在研抗肿瘤新药注射用JJH201601脂质体获得药物临床试验批准通知书，同意联合用药在晚期头颈部鳞癌中开展临床试验公司公告汇总吉贝尔自愿披露关于在研抗肿瘤新药注射用JJH201601脂质体获得药物临床试验批准通知书的公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071300000708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","BK1576","688566","BK1583","03347","BK0239"],"gpt_icon":0},{"id":"2551916139","title":"每周股票复盘：博瑞医药（688166）噻托溴铵吸入粉雾剂获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2551916139","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551916139?lang=zh_cn&edition=full","pubTime":"2025-07-13 02:29","pubTimestamp":1752344949,"startTime":"0","endTime":"0","summary":"截至2025年7月11日收盘，博瑞医药报收于60.62元，较上周的56.1元上涨8.06%。本周关注点公司公告汇总：博瑞医药控股子公司获得噻托溴铵吸入粉雾剂临床试验批准通知书公司公告汇总博瑞生物医药（苏州）股份有限公司控股子公司艾特美（苏州）医药科技有限公司近日收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意艾特美噻托溴铵吸入粉雾剂开展用于慢性阻塞性肺疾病的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071300000339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","BK0239","BK1141","BK1583","688166","03347"],"gpt_icon":0},{"id":"2551916555","title":"每周股票复盘：微芯生物（688321）西达本胺III期临床试验获顶线分析数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2551916555","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551916555?lang=zh_cn&edition=full","pubTime":"2025-07-13 02:13","pubTimestamp":1752343989,"startTime":"0","endTime":"0","summary":"截至2025年7月11日收盘，微芯生物报收于33.8元，较上周的31.0元上涨9.03%。本周，微芯生物7月7日盘中最高价报34.95元，股价触及近一年最高点。本周关注点公司公告汇总：西达本胺一线治疗弥漫大B细胞淋巴瘤的III期临床试验获得顶线分析数据公司公告汇总微芯生物自主研发的西达本胺针对一线治疗弥漫大B细胞淋巴瘤的关键性III期临床试验获得顶线分析数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071300000279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","03347","BK1583","688321","BK1576","BK0239"],"gpt_icon":0},{"id":"2550939739","title":"每日卖空追踪 | 泰格医药 07月11日卖空量成交20.98万股，卖空比例为2.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550939739","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550939739?lang=zh_cn&edition=full","pubTime":"2025-07-11 16:30","pubTimestamp":1752222633,"startTime":"0","endTime":"0","summary":"泰格医药北京时间07月11日，涨3.94%，卖空量成交20.98万股%，较上一交易日减少84.4%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711172652a44480fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711172652a44480fe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1141","03347","BK1583"],"gpt_icon":0},{"id":"2550988324","title":"泰格医药盘中异动 急速上涨5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550988324","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550988324?lang=zh_cn&edition=full","pubTime":"2025-07-11 13:39","pubTimestamp":1752212372,"startTime":"0","endTime":"0","summary":"2025年07月11日下午盘13时39分，泰格医药股票出现波动，股价急速上涨5.08%。截至发稿，该股报50.650港元/股，成交量381.45万股，换手率3.10%，振幅5.29%。机构评级方面，在所有12家参与评级的机构中，58%的券商给予买入建议，25%的券商给予持有建议，17%的券商给予卖出建议。泰格医药股票所在的生物技术行业中，整体涨幅为2.34%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071113393297a1df1e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071113393297a1df1e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1583","03347","BK1576"],"gpt_icon":0},{"id":"2550604944","title":"众生药业：ZSP1601片处于IIb期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2550604944","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550604944?lang=zh_cn&edition=full","pubTime":"2025-07-11 11:36","pubTimestamp":1752204965,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业07月11日在投资者关系平台上答复投资者关心的问题。公司按照“中药为基、创新引领，聚焦特色的医药健康企业”的战略目标定位，始终坚持以创新驱动发展，聚焦代谢性疾病、呼吸系统疾病等领域，积极推进创新药研发，其中，ZSP1601片是具有全新作用机制的治疗代谢功能障碍相关脂肪性肝炎的一类创新药，目前处于IIb期临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071100014853.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","BK1141","002317","BK1583","03347","BK1576","BK0188"],"gpt_icon":0},{"id":"2550614455","title":"吉贝尔(688566.SH)：在研抗肿瘤新药注射用JJH201601脂质体获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2550614455","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550614455?lang=zh_cn&edition=full","pubTime":"2025-07-10 16:36","pubTimestamp":1752136609,"startTime":"0","endTime":"0","summary":"智通财经APP讯，吉贝尔(688566.SH)发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研抗肿瘤新药注射用JJH201601脂质体临床试验申请符合药品注册的有关要求，同意本品联合西妥昔单抗(β)和/或特瑞普利单抗在晚期头颈部鳞癌中开展临床试验。注射用JJH201601脂质体是公司依托脂质体药物研发技术平台开发的抗肿瘤新药。公司通过分子设计和药效试验筛选，得到全新化合物，利用脂质体技术将其开发为脂质体制剂。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1316205.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","BK0239","BK1141","688566","03347","BK1583"],"gpt_icon":0},{"id":"2550069489","title":"联邦制药(03933)：UBT37034注射液获美国FDA新药临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2550069489","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550069489?lang=zh_cn&edition=full","pubTime":"2025-07-10 12:31","pubTimestamp":1752121888,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联邦制药 发布公告，于2025年7月4日，公司全资附属公司联邦生物科技有限公司研发的1类创新药UBT37034注射液关于超重或肥胖适应症的新药临床试验注册申请获美国食品药品监督管理局批准，IND编号为175188。UBT37034注射液是由联邦生物科技开发的具有独立自主知识产权的1类创新药。UBT37034是一款新型多肽类受体激动剂，可通过选择性作用于神经肽Y2受体减轻体重。临床前多种动物模型研究结果显示，UBT37034与GLP-1类似物联用能够显著降低体重。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1316097.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","03933","BK1191","BK1583","BK1576","03347"],"gpt_icon":0},{"id":"2550633639","title":"智飞生物最新公告：重组带状疱疹疫苗（CHO细胞）获得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2550633639","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550633639?lang=zh_cn&edition=full","pubTime":"2025-07-09 18:40","pubTimestamp":1752057618,"startTime":"0","endTime":"0","summary":"智飞生物(300122.SZ)公告称，公司全资子公司智飞龙科马研发的重组带状疱疹疫苗（CHO细胞）获得国家药品监督管理局药物临床试验批准通知书，同意在40岁及以上人群中开展用于预防带状疱疹的临床试验。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070900031537.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","BK1141","BK0239","BK0188","BK1576","159646","300122","LU2580892789.USD","03347","BK0046","LU1328615791.USD","BK0196","LU2580892862.HKD","BK0077","LU2148510915.USD","LU1064131003.USD","BK1583"],"gpt_icon":0},{"id":"2550069684","title":"复星医药子公司启动复迈宁®儿童脑胶质瘤Ⅲ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2550069684","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550069684?lang=zh_cn&edition=full","pubTime":"2025-07-09 16:37","pubTimestamp":1752050252,"startTime":"0","endTime":"0","summary":"7月9日，复星医药发布公告，控股子公司药品临床试验进展情况。公告指出，该公司控股子公司上海复星医药产业发展有限公司已启动复迈宁用于治疗儿童低级别脑胶质瘤的Ⅲ期临床试验。与此同时，该药品用于成人Ⅰ型神经纤维瘤病和儿童低级别脑胶质瘤的临床试验均处于Ⅲ期阶段，涉及的其他适应症也在进行相关临床试验。2025年一季度，复星医药实现收入94.20亿元，归母净利润7.65亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709163825953bec38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709163825953bec38&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02196","BK1576","03347","BK1593","BK1515","BK1583","BK1141"],"gpt_icon":0},{"id":"2550635939","title":"每日卖空追踪 | 泰格医药 07月09日卖空量成交85.54万股，卖空比例为7.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550635939","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550635939?lang=zh_cn&edition=full","pubTime":"2025-07-09 16:30","pubTimestamp":1752049834,"startTime":"0","endTime":"0","summary":"泰格医药北京时间07月09日，涨6.75%，卖空量成交85.54万股%，较上一交易日增加18.18%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709172543a440060d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709172543a440060d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1141","03347","BK1583"],"gpt_icon":0},{"id":"2550341689","title":"微芯生物(688321.SH)：西达本胺一线治疗弥漫大B细胞淋巴瘤的III期临床试验获顶线分析数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2550341689","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550341689?lang=zh_cn&edition=full","pubTime":"2025-07-09 16:02","pubTimestamp":1752048130,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微芯生物 公告，公司自主研发的西达本胺针对一线治疗弥漫大B细胞淋巴瘤关键性III期临床试验已于近日获得最终结果的顶线分析数据，试验组无事件生存期显著优于对照组，达成研究主要终点。西达本胺作用于表观遗传相关靶点组蛋白去乙酰化酶。此次顶线分析中，试验组无事件生存期较对照组展现具统计学显著意义的差异，进一步验证了西达本胺联合方案可为初治MYC和BCL2双表达DLBCL患者带来显著且可持续的疗效，且安全性良好。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688321","03347","III","BK1583","BK0239","BK4134","BK1576","BK1141"],"gpt_icon":0},{"id":"2550505560","title":"泰格医药盘中异动 急速拉升5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550505560","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550505560?lang=zh_cn&edition=full","pubTime":"2025-07-09 10:30","pubTimestamp":1752028256,"startTime":"0","endTime":"0","summary":"2025年07月09日早盘10时30分，泰格医药股票出现异动，股价大幅拉升5.03%。截至发稿，该股报45.900港元/股，成交量412.67万股，换手率3.35%，振幅6.64%。机构评级方面，在所有13家参与评级的机构中，62%的券商给予买入建议，23%的券商给予持有建议，15%的券商给予卖出建议。泰格医药股票所在的生物技术行业中，整体涨幅为0.79%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709103056a43f3312&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709103056a43f3312&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","03347","BK1141","BK1583"],"gpt_icon":0},{"id":"2549545314","title":"上海莱士(002252.SZ)：SR604注射液进入Ⅱb期临床试验研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2549545314","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549545314?lang=zh_cn&edition=full","pubTime":"2025-07-08 18:07","pubTimestamp":1751969270,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海莱士 公告，公司近日在国家药品监督管理局药物临床试验登记与信息公示平台公示了IIb期临床试验登记信息，试验名称为：评价SR604注射液在血友病A/B及先天性凝血因子Ⅶ缺乏症患者中的安全性、耐受性、有效性、PK/PD特征的开放、多中心Ⅰ/Ⅱ期临床试验。据公告所示，SR604注射液拟用于血友病A/B及先天性凝血因子Ⅶ缺乏症患者出血的预防治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315245.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0028","03347","BK1576","002252","BK0196","BK0046","BK1583","BK0239","BK1141"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tigermed.net","stockEarnings":[{"period":"1week","weight":0.2417},{"period":"1month","weight":0.1841},{"period":"3month","weight":0.8824},{"period":"6month","weight":0.7203},{"period":"1year","weight":0.7113},{"period":"ytd","weight":0.589}],"compareEarnings":[{"period":"1week","weight":0.0132},{"period":"1month","weight":0.013},{"period":"3month","weight":0.1275},{"period":"6month","weight":0.255},{"period":"1year","weight":0.3231},{"period":"ytd","weight":0.2065}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"杭州泰格医药科技股份有限公司是一家从事为新药研发提供临床试验服务的中国控股公司。该公司经营两个分部。临床试验技术服务分部向生物制药和医疗器械公司提供临床试验运作服务和医学翻译等服务，帮助其进行创新药物、仿制药和医疗器械的临床试验。临床试验相关服务及实验室服务分部从事提供分析服务，比如数据管理和统计分析；后勤和执行支持服务，比如临床试验现场管理；行政协助，比如患者招募；以及咨询服务等。该分部同时通过其子公司为临床前和临床开发阶段提供实验室服务。该公司在国内市场和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.098232},{"month":2,"riseRate":0.6,"avgChangeRate":0.03358},{"month":3,"riseRate":0.6,"avgChangeRate":-0.015344},{"month":4,"riseRate":0.2,"avgChangeRate":-0.055126},{"month":5,"riseRate":0.4,"avgChangeRate":0.024418},{"month":6,"riseRate":0.6,"avgChangeRate":0.024718},{"month":7,"riseRate":0.6,"avgChangeRate":0.041882},{"month":8,"riseRate":0,"avgChangeRate":-0.073439},{"month":9,"riseRate":0.4,"avgChangeRate":0.041745},{"month":10,"riseRate":0.4,"avgChangeRate":-0.034537},{"month":11,"riseRate":0.4,"avgChangeRate":0.029033},{"month":12,"riseRate":0.4,"avgChangeRate":0.03356}],"exchange":"SEHK","name":"泰格医药","nameEN":"TIGERMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰格医药(03347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰格医药,03347,泰格医药股票,泰格医药股票老虎,泰格医药股票老虎国际,泰格医药行情,泰格医药股票行情,泰格医药股价,泰格医药股市,泰格医药股票价格,泰格医药股票交易,泰格医药股票购买,泰格医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰格医药(03347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}